<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ooms M</submitter><funding>Intramural NIH HHS</funding><funding>NCRR NIH HHS</funding><funding>NIMH NIH HHS</funding><pagination>1306-1313</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC6668514</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>39(7)</volume><pubmed_abstract>Although still a matter of controversy, disrupted in schizophrenia protein 1 (DISC1) was suggested as a potential inhibitor of phosphodiesterase 4 (PDE4). We used Disc1 locus impairment (LI) mice to investigate the interaction between PDE4 and DISC 1 in vivo and in vitro. [11C](R)-Rolipram binding was measured by PET in LI (n = 11) and C57BL/6 wild-type (WT, n = 9) mice. [11C](R)-Rolipram total distribution volumes (VT) were calculated and corrected for plasma-free fraction (fP) measured in a separate group of LI (n = 6) and WT (n = 7) mice. PDE4 enzyme activity was measured using in vitro samples of cerebral cortices from groups of LI (n = 4), heterozygote (n = 4), and WT (n = 4) mice. Disc1 LI mice showed a 41% increase in VT (18 ± 6 vs. 13±4 mL/cm3, P = 0.04) compared to WT mice. VT/fP </pubmed_abstract><journal>Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism</journal><pubmed_title>[11C](R)-Rolipram positron emission tomography detects DISC1 inhibition of phosphodiesterase type 4 in live Disc1 locus-impaired mice.</pubmed_title><pmcid>PMC6668514</pmcid><funding_grant_id>ZIA MH002795</funding_grant_id><funding_grant_id>P50 MH094268</funding_grant_id><funding_grant_id>ZIA MH002793</funding_grant_id><funding_grant_id>R01 MH105660</funding_grant_id><funding_grant_id>P41 RR001192</funding_grant_id><pubmed_authors>Lohith TG</pubmed_authors><pubmed_authors>Jaaro-Peled H</pubmed_authors><pubmed_authors>Mabins SN</pubmed_authors><pubmed_authors>Kimura Y</pubmed_authors><pubmed_authors>Fujita M</pubmed_authors><pubmed_authors>Zoghbi SS</pubmed_authors><pubmed_authors>Innis RB</pubmed_authors><pubmed_authors>Sawa A</pubmed_authors><pubmed_authors>Ooms M</pubmed_authors><pubmed_authors>Tomoda T</pubmed_authors><pubmed_authors>Telu S</pubmed_authors><pubmed_authors>Tsujikawa T</pubmed_authors><pubmed_authors>Sumitomo A</pubmed_authors><pubmed_authors>Pike VW</pubmed_authors></additional><is_claimable>false</is_claimable><name>[11C](R)-Rolipram positron emission tomography detects DISC1 inhibition of phosphodiesterase type 4 in live Disc1 locus-impaired mice.</name><description>Although still a matter of controversy, disrupted in schizophrenia protein 1 (DISC1) was suggested as a potential inhibitor of phosphodiesterase 4 (PDE4). We used Disc1 locus impairment (LI) mice to investigate the interaction between PDE4 and DISC 1 in vivo and in vitro. [11C](R)-Rolipram binding was measured by PET in LI (n = 11) and C57BL/6 wild-type (WT, n = 9) mice. [11C](R)-Rolipram total distribution volumes (VT) were calculated and corrected for plasma-free fraction (fP) measured in a separate group of LI (n = 6) and WT (n = 7) mice. PDE4 enzyme activity was measured using in vitro samples of cerebral cortices from groups of LI (n = 4), heterozygote (n = 4), and WT (n = 4) mice. Disc1 LI mice showed a 41% increase in VT (18 ± 6 vs. 13±4 mL/cm3, P = 0.04) compared to WT mice. VT/fP </description><dates><release>2019-01-01T00:00:00Z</release><publication>2019 Jul</publication><modification>2025-04-04T13:33:05.552Z</modification><creation>2025-04-04T13:33:05.552Z</creation></dates><accession>S-EPMC6668514</accession><cross_references><pubmed>29430995</pubmed><doi>10.1177/0271678x18758997</doi><doi>10.1177/0271678X18758997</doi></cross_references></HashMap>